Advertisement

Breast Cancer Research and Treatment

, Volume 109, Issue 2, pp 231–239 | Cite as

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

  • Emilio Bria
  • Federica Cuppone
  • Monica Fornier
  • Cecilia Nisticò
  • Paolo Carlini
  • Michele Milella
  • Isabella Sperduti
  • Edmondo Terzoli
  • Francesco Cognetti
  • Diana Giannarelli
Review

Abstract

Background In five randomized clinical trials (RCTs), adjuvant trastuzumab (T) for early stage breast cancer with human epidermal growth-factor receptor-2 over-expression/gene-amplification has shown to decrease the risk of both recurrence and death. The issue regarding the long-term safety profile of such drug is still open; in particular, questions remain about long-term cardiotoxicity, and specific patterns of relapse such as brain metastases (BM). In order to quantify the magnitude of these two risks, and then balance those with the survival outcome, a literature-based meta-analysis was performed. Methods All phase III trials were considered eligible. A literature-based meta-analysis was accomplished, and event-based relative risk ratios with 95% confidence interval were derived. A fixed- and a random-effect model according to the inverse variance and the Mantel–Haenzel method were applied. Heterogeneity test was applied as well. Absolute differences (AD) and the Number of patients Needed to Treat or to Harm (NNT/NNH) were calculated. Safety end-points were: (1) Chronic Heart Failure (CHF) grade III-IV rate, (2) Significant reduction of left-ventricular-ejection-fraction (L-FEV) rate and (3) BM rate. In order to quantify the magnitude of the significant benefit already found in the original RCTs, Efficacy end-points were: (1) disease-free survival (DFS) and (2) overall survival (OS). Results Five RCTs were gathered (11,187 patients); at an average 2-years follow-up, all data was available for the safety and efficacy end-points, while three RCTs reported results for BM analysis (6,738 patients). When considering RCTs with trastuzumab administered for 1 year, a significant increased risk of grade III–IV Congestive Heart Failure (CHF) was found in the T-arm, with an AD of 1.61% (p < 0.00001), which translates into 62 treated patients required to harm one (NNH). When considering the asymptomatic L-FEV reduction, a significant increased risk of grade significant L-FEV reduction was found in the T-arm, although significantly heterogeneous, with an AD of 7.20% (p < 0.00001), which translates into 14 NNH. The incidence of BM was significantly higher in the T-arm, without significant heterogeneity, with an AD of 0.62 (p = 0.033), which translates into 161 NNH. The DFS, DDFS, and OS were significantly better in the T-arm, with an AD of 6.00, 4.80 and 1.96%, which translates into 16, 21 and 51 NNT, respectively. Conclusions The overall outcome results show that trastuzumab is one of the most important discoveries in oncology. Nevertheless, the biological activity of trastuzumab needs to be investigated more extensively to explore both long-term safety and specific relapse patterns.

Keywords

Trastuzumab Adjuvant Meta-analysis Cardiotoxicity Brain metastases 

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ 2006 Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712PubMedCrossRefGoogle Scholar
  3. 3.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182PubMedCrossRefGoogle Scholar
  4. 4.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792PubMedCrossRefGoogle Scholar
  5. 5.
    Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19):4265–4274PubMedCrossRefGoogle Scholar
  6. 6.
    Osoba D, Slamon DJ, Burchmore M, Murphy M (2002) Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20(14):3106–3113PubMedCrossRefGoogle Scholar
  7. 7.
    Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676–3685PubMedCrossRefGoogle Scholar
  8. 8.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672PubMedCrossRefGoogle Scholar
  9. 9.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684PubMedCrossRefGoogle Scholar
  10. 10.
    Slamon D, Eiermann W, Robert N, -006 oboB (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/ETH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. In: Proceedings of San Antonio breast cancer symposium (SABCS): 2006, San Antonio. Breast Cancer Research and TreatmentGoogle Scholar
  11. 11.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809–820PubMedCrossRefGoogle Scholar
  12. 12.
    Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23(31):7820–7826PubMedCrossRefGoogle Scholar
  13. 13.
    Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ (2006) Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11(8):857–867PubMedCrossRefGoogle Scholar
  14. 14.
    Duchnowska R, Szczylik C (2005) Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 31(4):312–318PubMedCrossRefGoogle Scholar
  15. 15.
    Pignon JP, Hill C (2001) Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2(8):475–482PubMedCrossRefGoogle Scholar
  16. 16.
    Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, Natoli G, Terzoli E, Cognetti F, Giannarelli D (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 106(11):2337–2344PubMedCrossRefGoogle Scholar
  17. 17.
    Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5):1215–1221PubMedCrossRefGoogle Scholar
  18. 18.
    Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R (2002) Interpreting measures of treatment effect in cancer clinical trials. Oncologist 7(3):181–187PubMedCrossRefGoogle Scholar
  19. 19.
    Parmar M, Machin D (1995) Survival analysis: a practical approach. Wiley, ChichesterGoogle Scholar
  20. 20.
    Altman DG (1998) Confidence intervals for the number needed to treat. BMJ 317(7168):1309–1312PubMedGoogle Scholar
  21. 21.
    Geyer CE Jr, Bryant JL, Romond EH, Ewer MS, Keefe DL, Shannon RP, Levine TB, Rastogi P, Swain SM, Wolmark N (2006) Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab (H). J Clin Oncol 24:581Google Scholar
  22. 22.
    Perez EA, Suman VJ, Davidson NE et al (2005) Interim cardiac safety analysis of NCCTG N9831 intergroup adjuvant trastuzumab trial. In: Proceeding of the American society of clinical oncology meeting: 2005, OrlandoGoogle Scholar
  23. 23.
    Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS (2005) Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? In: Proceedings of San Antonio breast cancer symposium meeting: 2005, San Antonio. Breast Cancer Research and TreatmentGoogle Scholar
  24. 24.
    Smith I, team oboH (2006) Trastuzumab following adjuvant chemotherapy in HER-2-positive Early Breast Cancer (HERA): disease-free and overall survival after 2-year median follow-up. Proceedings of American Society of Clinical Oncology Meeting (ASCO): 2006, AtlantaGoogle Scholar
  25. 25.
    Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811–7819PubMedCrossRefGoogle Scholar
  26. 26.
    Slamon D, Eiermann, W, Robert, N on behalf of BCIRG -006 (2005) Phase III trial comparing ACT with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim efficacy analysis. In: Proceedings of San Antonio Breast Cancer Symposium (SABCS): 2005, San AntonioGoogle Scholar
  27. 27.
    Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) Lancet 365(9472):1687–1717Google Scholar
  28. 28.
    Baselga J, Perez EA, Pienkowski T, Bell R (2006) Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11(Suppl 1):4–12PubMedCrossRefGoogle Scholar
  29. 29.
    Halyard MY, Pisansky TM, Solin LJ, Marks LB, Pierce LJ, Dueck A, Perez EA (2006) Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group Phase III trial N9831, vol 24. p 523Google Scholar
  30. 30.
    Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381–5387PubMedCrossRefGoogle Scholar
  31. 31.
    Smith KL, Dang C, Seidman AD (2006) Cardiac dysfunction associated with trastuzumab. Expert opinion on drug safety 2006 5(5):619–629CrossRefGoogle Scholar
  32. 32.
    Sledge GW, O’Neill A, Thor AD, Kahanic SP, Zander PJ, Davidson NE (2006) Adjuvant trastuzumab: long-term results of E2198. In: Proccedings of San Antonio Breast Cancer Symposium Meeting (SABCS): 2006, San Antonio. Breast Cancer Research and TreamentGoogle Scholar
  33. 33.
    Moy B, Goss PE (2006) Lapatinib: current status and future directions in breast cancer. Oncologist 11(10):1047–1057PubMedCrossRefGoogle Scholar
  34. 34.
    Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Emilio Bria
    • 1
  • Federica Cuppone
    • 1
  • Monica Fornier
    • 2
  • Cecilia Nisticò
    • 1
  • Paolo Carlini
    • 1
  • Michele Milella
    • 1
  • Isabella Sperduti
    • 3
    • 1
  • Edmondo Terzoli
    • 1
  • Francesco Cognetti
    • 1
  • Diana Giannarelli
    • 3
  1. 1.Department of Medical OncologyRegina Elena National Cancer InstituteRomeItaly
  2. 2.Breast Cancer Medicine ServiceMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.BiostatisticsRegina Elena National Cancer InstituteRomeItaly

Personalised recommendations